Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Other neoplasm 1

Conditions

Skin Diseases 1Precancerous Conditions 1Keratosis, Actinic 1Keratosis 1

Interventions

Biopsy 4Cyclophosphamide 3Microarray Analysis 2Methylprednisolone 2Filgrastim 2Colposcopy 2Carboplatin 2toripalimab 1tipifarnib 1sargramostim 1sapanisertib 1pyroxamide 1pirfenidone 1penpulimab 1palbociclib 1liposomal doxorubicin 1iodixanol 1human papillomavirus vaccine, TA 1artemisinin 1arginine butyrate 1Zoledronic Acid 1Vincristine 1Video-Assisted Surgery 1Topotecan 1Tetradecanoylphorbol Acetate 1Taxes 1Tacrolimus 1Specimen Handling 1Sorafenib 1Sodium Chloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × BF-200 ALA × Other neoplasm × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡